Spotlight
Specialty
Partners
CME/CE
Advanced Endometrial Cancer: Treatment Optimization : Episode 10
Adverse Events Seen With Combination Lenvatinib and Pembrolizumab for Recurrent Endometrial Cancer
Kimberly A. Spickes, CNP, details the adverse events she sees with combination lenvatinib and pembrolizumab treatment for recurrent endometrial cancer.
EP: 1.Patient Profile Presentation: A 76-Year-Old Woman With Advanced Endometrial Cancer
EP: 2.Fertility and Other Treatment Considerations for Patients With Advanced Endometrial Cancer
EP: 3.Currently Available Treatment Modalities in Endometrial Cancer
EP: 4.First-Line Treatments for Patients With Advanced Endometrial Cancer Who Are Unfit for Surgery
EP: 5.Common Adverse Events Seen With Chemotherapy for Advanced Endometrial Cancer
EP: 6.Efficacy of Chemotherapy in Patients with Advanced Endometrial Cancer
EP: 7.Treatment Options for Patients with Recurrent Endometrial Cancer
EP: 8.Educating Patients With Endometrial Cancer on Treatment-Related Adverse Events
EP: 9.Monitoring Patients on Therapy for Recurrent Endometrial Cancer
Now Viewing
EP: 10.Adverse Events Seen With Combination Lenvatinib and Pembrolizumab for Recurrent Endometrial Cancer
EP: 11.Proactive Adverse Effect Management for Patients on Therapy for Endometrial Cancer
EP: 12.Discussing Dose Reductions and Interruptions with Patients on Therapy for Endometrial Cancer
EP: 13.Greatest Unmet Needs for Patients with Endometrial Cancer
EP: 14.Advice for New Nurse Practitioners Working With Patients With Endometrial Cancer
Related Videos
Related Content
